ITPB 1 vs 3 in VATS
Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 17, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well patients recover after a specific type of lung surgery called video-assisted thoracoscopic surgery (VATS). The researchers want to compare two different techniques for pain relief during the surgery: one that targets a single area of the spine and another that targets three areas. They will measure recovery quality using a simple survey called the QoR15, which helps understand how patients feel 24 hours after the surgery.
To take part in the study, participants need to be between 18 and 80 years old and scheduled for lung surgery due to lung cancer. People who are generally healthy (classified as ASA I-III) can join, but those who refuse to participate, have infections where the injection would go, or have certain health issues won’t be eligible. If you join this trial, you can expect to be closely monitored after your surgery to see how well each pain relief method works. Overall, this study aims to improve recovery experiences for future patients undergoing similar procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA I-III patients
- • 18 to 80 years of age
- • Patients with primary carcinoma lung scheduled for resection under VATS procedure
- Exclusion Criteria:
- • Patient refusal
- • Local skin infection at the area of injection
- • Coagulopathy
- • History of allergy to local anaesthetics
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Territories, , Hong Kong
Patients applied
Trial Officials
Manoj K Karmakar, MD, FRCA
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported